A new HPLC MS method to determine loratadine in human plasma was established. The method involved extracting drug with organic solvent under basic conditions. The samples were seperated by ODS column and determined ...A new HPLC MS method to determine loratadine in human plasma was established. The method involved extracting drug with organic solvent under basic conditions. The samples were seperated by ODS column and determined by mass detector. The calibration curve of loratadine was linear within the range of 0.4～100 ng·mL -1 with r=0.9995 . The recovery of this method was within 95%～104%, within day and between day RSD were less than 12%. To study the pharmacokinetics and relative bioavailability of loratadine tablets, two formulations of loratadine tablets were given to 18 healthy male volunteers according to a randomized 2 way cross over design. The C max , AUC 0 t and T max values of the two formulations were 51.89±20.18 ng·mL -1 and 52.48±22.35 ng·mL -1 ; 140.75±88.42 ng·h·mL -1 and 147.24±92.33 ng·h·mL -1 ; 0.81±0.35 h and 0.81±0.27 h respectively. Results from statistic analysis showed that there were no significant difference between the C max , AUC 0-t and T max values of the two formulations. The relative bioavailability of tablets I with respect to tablets II was 97%±13% from the AUC 0 t measurement. Bioequivalance was observed between the two tablets.展开更多
Objective:To evaluate the cytokine levels and immune response status of montelukast, loratadine and tanshinone combination therapy for Henoch-Schonlein purpura.Methods: A total of 80 patients with Henoch-Schonlein pur...Objective:To evaluate the cytokine levels and immune response status of montelukast, loratadine and tanshinone combination therapy for Henoch-Schonlein purpura.Methods: A total of 80 patients with Henoch-Schonlein purpura who were treated in Ankang Central Hospital between May 2014 and January 2017 were collected and divided into montelukast group, loratadine group, tanshinone group and combined treatment group according to the random number table, 20 cases in each group. Serum levels of inflammatory factors, Th17/Treg cellular immunity indexes before and after treatment were compared among four groups of patients.Results: Before treatment, differences in serum levels of inflammatory factors and Th17/Treg cellular immunity indexes were not statistically significant among four groups of patients. After treatment, serum HMGB1, IL-8, IL-14, IL-23 and IL-33 levels in combined treatment group were lower than those in montelukast group, loratadine group and tanshinone group;serum IL-17 level was lower than that in montelukast group, loratadine group and tanshinone group while IL-10 and TGF-β levels were higher than those in montelukast group, loratadine group and tanshinone group.Conclusions: Montelukast, loratadine and tanshinone combination therapy for Henoch-Schonlein purpura helps to reduce systemic inflammatory response and balance Th17/Treg cell immunity.展开更多
Objective To explore the efficacy of mild moxibustion plus loratadine tablets for children with allergic rhinitis(AR).Methods A total of 80 children were randomized into a control group and an observation group,with 4...Objective To explore the efficacy of mild moxibustion plus loratadine tablets for children with allergic rhinitis(AR).Methods A total of 80 children were randomized into a control group and an observation group,with 40 cases in each group.The control group was treated with loratadine tablets,and the observation group was treated with mild moxibustion plus loratadine tablets.Before and after treatment,the total nasal symptom score(TNSS)was evaluated,and the serum eosinophils(EOS)count,and the interleukin(IL)-27 and macrophage migration inhibitory factor(MIF)levels were measured.Clinical efficacy was evaluated after treatment.Results The total effective rate of the observation group was higher than that of the control group(P<0.05).After treatment,the TNSS in both groups decreased(P<0.05),and the TNSS in the observation group was lower than that in the control group(P<0.05);the serum EOS count in both groups decreased(P<0.05),and the serum EOS count in the observation group was lower than that in the control group(P<0.05).The serum IL-27 level in the control group had no statistical difference compared with the same group before treatment(P>0.05),and the serum MIF level decreased after treatment(P<0.05).The serum IL-27 level in the observation group increased after treatment(P<0.05),and the serum MIF level decreased after treatment(P<0.05),and were both statistically different from those in the control group(P<0.05).Conclusion Mild moxibustion plus loratadine tablets is effective in treating children with AR.It can significantly improve the nasal symptoms and reduce the serum EOS count,which may be related to the regulation of the serum IL-27 and MIF levels.展开更多
Objective： To discuss the clinical efficacy of Liu＇s infantile tuina therapy in treating kid＇s allergic rhinitis （AR）. Methods： Sixty eligible AR kids were randomized into a tuina group and a Western medication ...Objective： To discuss the clinical efficacy of Liu＇s infantile tuina therapy in treating kid＇s allergic rhinitis （AR）. Methods： Sixty eligible AR kids were randomized into a tuina group and a Western medication group by their visiting sequence, 30 cases in each group. The tuina group was intervened by Liu＇s infantile tuina therapy, once daily, 5 times as a treatment course, with a 2-day interval after a course; the control group was by orally taking Loratadine. The therapeutic efficacies were compared and analyzed after treatment for 4 successive weeks. Results： After treatment, the symptoms such as itchy nose, sneezing, runny nose, and stuffy nose were significantly improved in both groups （P〈0.05）, and the improvements in the tuina group were more remarkable than those in the Western medication group （P〈0.05）. The total effective rate was 90.0% in the tuina group versus 73.3% in the Western medication group, and the difference was statistically significant （P〈0.05）. Conclusion： Liu＇s infantile tuina therapy can produce a better therapeutic efficacy in treating AR kids compared to oral administration of Loratadine.展开更多
文摘A new HPLC MS method to determine loratadine in human plasma was established. The method involved extracting drug with organic solvent under basic conditions. The samples were seperated by ODS column and determined by mass detector. The calibration curve of loratadine was linear within the range of 0.4～100 ng·mL -1 with r=0.9995 . The recovery of this method was within 95%～104%, within day and between day RSD were less than 12%. To study the pharmacokinetics and relative bioavailability of loratadine tablets, two formulations of loratadine tablets were given to 18 healthy male volunteers according to a randomized 2 way cross over design. The C max , AUC 0 t and T max values of the two formulations were 51.89±20.18 ng·mL -1 and 52.48±22.35 ng·mL -1 ; 140.75±88.42 ng·h·mL -1 and 147.24±92.33 ng·h·mL -1 ; 0.81±0.35 h and 0.81±0.27 h respectively. Results from statistic analysis showed that there were no significant difference between the C max , AUC 0-t and T max values of the two formulations. The relative bioavailability of tablets I with respect to tablets II was 97%±13% from the AUC 0 t measurement. Bioequivalance was observed between the two tablets.
文摘Objective:To evaluate the cytokine levels and immune response status of montelukast, loratadine and tanshinone combination therapy for Henoch-Schonlein purpura.Methods: A total of 80 patients with Henoch-Schonlein purpura who were treated in Ankang Central Hospital between May 2014 and January 2017 were collected and divided into montelukast group, loratadine group, tanshinone group and combined treatment group according to the random number table, 20 cases in each group. Serum levels of inflammatory factors, Th17/Treg cellular immunity indexes before and after treatment were compared among four groups of patients.Results: Before treatment, differences in serum levels of inflammatory factors and Th17/Treg cellular immunity indexes were not statistically significant among four groups of patients. After treatment, serum HMGB1, IL-8, IL-14, IL-23 and IL-33 levels in combined treatment group were lower than those in montelukast group, loratadine group and tanshinone group;serum IL-17 level was lower than that in montelukast group, loratadine group and tanshinone group while IL-10 and TGF-β levels were higher than those in montelukast group, loratadine group and tanshinone group.Conclusions: Montelukast, loratadine and tanshinone combination therapy for Henoch-Schonlein purpura helps to reduce systemic inflammatory response and balance Th17/Treg cell immunity.
文摘Objective To explore the efficacy of mild moxibustion plus loratadine tablets for children with allergic rhinitis(AR).Methods A total of 80 children were randomized into a control group and an observation group,with 40 cases in each group.The control group was treated with loratadine tablets,and the observation group was treated with mild moxibustion plus loratadine tablets.Before and after treatment,the total nasal symptom score(TNSS)was evaluated,and the serum eosinophils(EOS)count,and the interleukin(IL)-27 and macrophage migration inhibitory factor(MIF)levels were measured.Clinical efficacy was evaluated after treatment.Results The total effective rate of the observation group was higher than that of the control group(P<0.05).After treatment,the TNSS in both groups decreased(P<0.05),and the TNSS in the observation group was lower than that in the control group(P<0.05);the serum EOS count in both groups decreased(P<0.05),and the serum EOS count in the observation group was lower than that in the control group(P<0.05).The serum IL-27 level in the control group had no statistical difference compared with the same group before treatment(P>0.05),and the serum MIF level decreased after treatment(P<0.05).The serum IL-27 level in the observation group increased after treatment(P<0.05),and the serum MIF level decreased after treatment(P<0.05),and were both statistically different from those in the control group(P<0.05).Conclusion Mild moxibustion plus loratadine tablets is effective in treating children with AR.It can significantly improve the nasal symptoms and reduce the serum EOS count,which may be related to the regulation of the serum IL-27 and MIF levels.
基金supported by Tuina Department of Yueyang Hospital of Traditional Chinese Medicine Affiliated to Hunan University of Chinese Medicine,National Clinical Key DepartmentTuina Science Key Project of the State Administration of Traditional Chinese Medicine+4 种基金Scientific Planning Project of Traditional Chinese Medicine of Hunan Province(No.201484)Fund Project of Hunan Province Education Office(No.15C1057)Tuina Special Techniques Key Laboratory of Administration of Traditional Chinese Medicine of Hunan ProvinceScience of Tuina Manipulations Excellent Course of Hunan ProvinceScience of Tuina Excellent Course of Hunan University of Chinese Medicine~~
文摘Objective： To discuss the clinical efficacy of Liu＇s infantile tuina therapy in treating kid＇s allergic rhinitis （AR）. Methods： Sixty eligible AR kids were randomized into a tuina group and a Western medication group by their visiting sequence, 30 cases in each group. The tuina group was intervened by Liu＇s infantile tuina therapy, once daily, 5 times as a treatment course, with a 2-day interval after a course; the control group was by orally taking Loratadine. The therapeutic efficacies were compared and analyzed after treatment for 4 successive weeks. Results： After treatment, the symptoms such as itchy nose, sneezing, runny nose, and stuffy nose were significantly improved in both groups （P〈0.05）, and the improvements in the tuina group were more remarkable than those in the Western medication group （P〈0.05）. The total effective rate was 90.0% in the tuina group versus 73.3% in the Western medication group, and the difference was statistically significant （P〈0.05）. Conclusion： Liu＇s infantile tuina therapy can produce a better therapeutic efficacy in treating AR kids compared to oral administration of Loratadine.
